WallStreetZenWallStreetZen

NASDAQ: NBP
Novabridge Biosciences Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NBP

Based on 4 analysts offering 12 month price targets for Novabridge Biosciences

Min Forecast
$6.00+72.41%
Avg Forecast
$7.75+122.7%
Max Forecast
$9.00+158.62%

Should I buy or sell NBP stock?

Based on 4 analysts offering ratings for Novabridge Biosciences.

Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NBP's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates NBP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their NBP stock forecasts and price targets.

NBP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-24
lockedlocked$00.00+00.00%2025-10-03
lockedlocked$00.00+00.00%2025-09-08
lockedlocked$00.00+00.00%2025-08-21

1 of 1

Forecast return on equity

Is NBP forecast to generate an efficient return?

Company
-15.18%
Industry
337.03%
Market
215.3%
NBP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NBP forecast to generate an efficient return on assets?

Company
-14.17%
Industry
118.5%
NBP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NBP earnings per share forecast

What is NBP's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.36
Avg 2 year Forecast
-$0.43
Avg 3 year Forecast
-$0.38

NBP revenue forecast

What is NBP's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$2.9M

NBP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NBP$3.48$7.75+122.70%Strong Buy
LCTX$1.76$5.50+212.50%Strong Buy
AVXL$4.39$22.00+401.14%Strong Buy
ZURA$6.32$11.50+81.96%Strong Buy
ENTA$13.57$20.40+50.33%Strong Buy
View Top Biotech Stocks

Novabridge Biosciences Stock Forecast FAQ

Is Novabridge Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: NBP) stock is to Strong Buy NBP stock.

Out of 4 analysts, 1 (25%) are recommending NBP as a Strong Buy, 3 (75%) are recommending NBP as a Buy, 0 (0%) are recommending NBP as a Hold, 0 (0%) are recommending NBP as a Sell, and 0 (0%) are recommending NBP as a Strong Sell.

If you're new to stock investing, here's how to buy Novabridge Biosciences stock.

What is NBP's earnings growth forecast for 2026-2028?

(NASDAQ: NBP) Novabridge Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.96%.

Novabridge Biosciences's earnings in 2026 is -$24,544,000.On average, 7 Wall Street analysts forecast NBP's earnings for 2026 to be -$95,514,008, with the lowest NBP earnings forecast at -$127,334,333, and the highest NBP earnings forecast at -$75,175,517. On average, 7 Wall Street analysts forecast NBP's earnings for 2027 to be -$115,163,059, with the lowest NBP earnings forecast at -$142,926,292, and the highest NBP earnings forecast at -$83,528,352.

In 2028, NBP is forecast to generate -$100,896,946 in earnings, with the lowest earnings forecast at -$158,518,251 and the highest earnings forecast at -$55,685,568.

What is NBP's revenue growth forecast for 2026-2028?

(NASDAQ: NBP) Novabridge Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.25%.

Novabridge Biosciences's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast NBP's revenue for 2026 to be $0, with the lowest NBP revenue forecast at $0, and the highest NBP revenue forecast at $0. On average, 5 Wall Street analysts forecast NBP's revenue for 2027 to be $0, with the lowest NBP revenue forecast at $0, and the highest NBP revenue forecast at $0.

In 2028, NBP is forecast to generate $781,984,481 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,065,046,488.

What is NBP's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NBP) forecast ROA is -14.17%, which is lower than the forecast US Biotechnology industry average of 118.5%.

What is NBP's Price Target?

According to 4 Wall Street analysts that have issued a 1 year NBP price target, the average NBP price target is $7.75, with the highest NBP stock price forecast at $9.00 and the lowest NBP stock price forecast at $6.00.

On average, Wall Street analysts predict that Novabridge Biosciences's share price could reach $7.75 by Oct 24, 2026. The average Novabridge Biosciences stock price prediction forecasts a potential upside of 122.7% from the current NBP share price of $3.48.

What is NBP's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NBP) Novabridge Biosciences's current Earnings Per Share (EPS) is -$0.30. On average, analysts forecast that NBP's EPS will be -$0.36 for 2026, with the lowest EPS forecast at -$0.48, and the highest EPS forecast at -$0.28. On average, analysts forecast that NBP's EPS will be -$0.43 for 2027, with the lowest EPS forecast at -$0.54, and the highest EPS forecast at -$0.32. In 2028, NBP's EPS is forecast to hit -$0.38 (min: -$0.60, max: -$0.21).

What is NBP's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NBP) forecast ROE is -15.18%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.